NRX Pharmaceuticals financials
$2.92+1.74%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $720.0K | $0.00 | $0.00 | $0.00 | — |
| Gross margin | 58.8% | — | — | — | — |
| Operating income | -$16.2M | -$18.5M | -$27.8M | -$44.3M | -$115.8M |
| Net income | -$28.6M | -$25.1M | -$30.2M | -$39.8M | -$348.9M |
| Net margin | −2336.5% | — | — | — | — |
| Diluted EPS | $-1.34 | $-2.36 | $-3.98 | $-6.00 | $-74.40 |
| EBITDA | -$16.1M | -$19.7M | -$27.6M | -$44.3M | -$115.8M |
| Operating cash flow | -$14.1M | -$10.6M | -$21.7M | -$39.8M | -$37.7M |
| Free cash flow | -$14.1M | -$10.6M | -$21.7M | -$39.8M | -$37.7M |
| Diluted shares | 21.4M | 10.6M | 7.6M | 6.6M | 4.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $7.8M | $1.4M | $4.6M | $20.1M | $27.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $6.6M | $9.2M | $10.5M | $518.0K |
| Total assets | $13.0M | $3.7M | $7.3M | $25.8M | $32.7M |
| Total liabilities | $28.9M | $26.9M | $19.0M | $18.4M | $11.9M |
| Shareholders' equity | -$15.9M | -$23.2M | -$11.7M | $7.4M | $20.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology